A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate (memsorb)

DMF Medical

Status: Enrolling

Conditions: Anesthesia

Treatments: Device: memsorb

Study type: Interventional

Funder types: Industry

Identifiers

NCT03014336

DMF-CLIN-16-01

Details and patient eligibility

About

The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

Full description

DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.

memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.

This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.

memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.

Enrollment: 450 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
• English-speaking patients

Exclusion criteria

• Self-reported as pregnant
• American Society of Anesthesiologists Physical Status Class IV (high risk patient)
• Patients scheduled for emergency surgery
• Documented respiratory disease, including COPD and severe asthma
• Documented elevated pressure in the brain (intra cranial pressure, ICP)

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

450 participants in 2 patient groups

Control

No Intervention group

Description:

Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.

memsorb

Experimental group

Description:

Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.

Treatment:

Device: memsorb